What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Main Authors: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
2010
|
פריטים דומים
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
מאת: Testa, L, et al.
יצא לאור: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
מאת: L. Testa, et al.
יצא לאור: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
מאת: Aparna Joshi, et al.
יצא לאור: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
מאת: Bhindi, R, et al.
יצא לאור: (2008) -
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
מאת: Testa, L, et al.
יצא לאור: (2009)